People in the News

Oct 23, 2017

Daniel Siegel

DermTech has appointed Daniel Siegel to its scientific advisory board. Siegel is currently a clinical professor of dermatology at SUNY Downstate. He has served as president of the American Academy of Dermatology and is a past member of both the Academy's board of directors and its coding and reimbursement task force. 

Oct 19, 2017

Douglas Berthiaume, Christopher O'Connell

Douglas Berthiaume is retiring as chairman of Waters' board, effective Dec. 31, 2017. Waters President and CEO Christopher O'Connell was elected the firm's new chairman. Berthiaume became president and CEO of Waters in 1994, when it split from Millipore, and he retired as the company's CEO in 2015. He took over as chairman of the firm in 1996. 

Oct 18, 2017

Carlos Bustamante

HumanCode has appointed Carlos Bustamante to its scientific advisory board. Bustamante is currently a professor of computational genomics and biomedical informatics at Stanford University. He will provide scientific guidance to the company following the launch of its BabyGlimpse DNA app for couples to explore the genetics of potential offspring.

Oct 18, 2017

Olivier Elemento and Anshul Kundaje

Freenome has announced the formation of its scientific advisory board including inaugural members Olivier Elemento and Anshul Kundaje.

Elemento is director of the Englander Institute for Precision Medicine, head of the Cancer Systems Biology Laboratory, and associate professor of computational genomics in computational biomedicine at Weill Cornell Medical College. He also serves as co-assistant dean for scientific computing, associate director of the Institute for Computational Biomedicine, and co-chair of the Genetics, Epigenetics and Systems Biology Program at the Meyer Cancer Center. 

Kundaje is an assistant professor of genetics and computer science at Stanford University, focused on computational regulatory genomics. He previously led integrative analysis efforts for the ENCODE Project and the Roadmap Epigenomics Project. 

According to Freenome, the new SAB will work closely with the company's management team to advance the development of the firm's technology platform and commercial disease screening products.

Oct 17, 2017

Kathryn McKenzie

Kathryn McKenzie has been appointed principal accounting officer and vice president of finance at NeoGenomics. Previously, she worked for Chico's FAS in several roles including assistant controller and director of financial reporting and treasury. She was also previously an audit manager for Ernst and Young.

Oct 13, 2017

Fred Hirsch

Biocept said that Fred Hirsch has joined its clinical advisory board. Hirsch is a professor of medicine and pathology at the University of Colorado Cancer Center.

Oct 11, 2017

Thomas Grogan

Thomas Grogan has joined the board of directors of ReadCoor. He is professor emeritus of pathology at the University of Arizona College of Medicine and a scientific advisor to Ventana Medical Systems, which he founded, and Roche Tissue Diagnostics. 

Oct 11, 2017

Tom Civik

Tom Civik has been appointed as chief commercial officer of Foundation Medicine and will start his new position in mid November. Most recently, he was a vice president and franchise leader at Genentech, where he was responsible for several oncology products. Earlier, he held various commercial positions at Sanofi-Synthelabo. Civik holds a BA from St. Norbert College and a master's degree in business administration from the Kellogg School of Management at Northwestern University.

Oct 10, 2017

Andrea Bodnar

Andrea Bodnar has joined the Gloucester Marine Genomics Institute as its first scientific director. Bodnar recently served as a senior scientist in the molecular lab of the Bermuda Institute of Ocean Science, and she previously held senior scientist posts in the oncology department at Hoffman-La Roche and at Geron. She will lead the non-profit institute's genomics-driven marine research efforts.

Oct 10, 2017

Greg Yap

Greg Yap is joining Menlo Ventures as a partner to lead investments in health, medical, and life science technologies. Yap was most recently an entrepreneur-in-residence at Illumina Ventures, where he focused on new genomics investments, and also co-founded and served as CEO of PyrAmes, a digital health company. Previously Yap was CEO and co-founder of protein analysis firm Biodesy. He has also held senior roles at Roche/Ventana and Affymetrix.

Oct 10, 2017

John Kenny

John Kenny has been appointed CEO of Meridian Bioscience, effective Oct. 9. He replaces John Kraeutler who is stepping down to become executive chairman. Kraeutler announced in May his plans to resign from the company as CEO. Kenny also was appointed to Meridian's board, effective Oct. 9. Kenny was most recently senior vice president, general manager, North America at Siemens Healthcare. He has also held executive level roles at Becton Dickinson, Leica Biosystems, and Quest Diagnostics.

Oct 09, 2017

California Precision Medicine Advisory Committee

California Gov. Edmund "Jerry" Brown has created the Governor's Advisory Committee on Precision Medicine and name some well-known figures to the 14-member panel. The committee will advise the governor's office on all matters related to precision medicine and make recommendations for statewide policy. Founding members are: 

  • Tomás Aragón, health officer of the City and County of San Francisco
  • Atul Butte, principal investigator of the California Initiative to Advance Precision Medicine at UC San Francisco
  • John Carpten, chair of the Department of Translational Genomics at the University of Southern California Keck School of Medicine
  • Jay Gellert, former president and CEO of Health Net
  • Kim Goodwin, author of "Designing for the Digital Age"
  • Stephen Lockhart, chief medical officer of Sutter Health
  • Kelsey Martin, dean of the David Geffen School of Medicine at UCLA
  • Mary Maxon, associate laboratory director for biosciences at Lawrence Berkeley National Laboratory
  • Jessica Mega, chief medical officer of Verily Life Sciences
  • Jill Mesirov, associate vice chancellor for computational health at UC San Diego School of Medicine
  • Frederick Meyers, associate dean for precision medicine at UC Davis Health
  • Arnold Milstein, director of the Clinical Excellence Research Center at Stanford University
  • Hakan Sakul, vice president of diagnostics at Pfizer
  • Sue Siegel, CEO of GE Ventures. 
Oct 05, 2017

Mark Lewis

Mark Lewis has become CEO of Swift Biosciences, replacing Tim Harkins. Most recently, he held senior vice president roles in product development, general management, and customer support at Illumina. Previously, Lewis held R&D, commercial, and general management roles at various other companies, including BD Biosciences, Molecular Dynamics, Nycomed-Amersham, and Beckman Instruments. He holds a BA in biology from the University of California, San Diego.

Oct 03, 2017

Alan Copperman

Alan Copperman has joined health information firm Sema4 as its chief medical officer. Copperman is director of the division of reproductive endocrinology and infertility, and vice chairman of the department of obstetrics, gynecology, and reproductive science at the Icahn School of Medicine at Mount Sinai. He also is managing partner at Reproductive Medicine Associates of New York. 

Oct 03, 2017

Jeffrey Rona

Jeffrey Rona has resigned from his position as CFO of Great Basin Scientific, effective October 6, 2017.

Oct 03, 2017

Paul Eros

Novacyt has appointed Paul Eros as commercial director, effective Nov. 1. Eros joins Novacyt from DiaSorin, where he was VP of molecular marketing for more than five years. He has also worked for Becton Dickinson and Roche Diagnostics

Oct 03, 2017

Jeffery Luber

Atlas Genetics announced today that Jeffrey Luber has been appointed CEO and John Clarkson, current founding CEO, will become Executive Chairman. Mr. Luber joins the board with experience in the life sciences industry, including roles in both public and private companies. Most recently, he led the return to growth and sale of Good Start Genetics to Invitae. Prior to this, Luber was CEO of Exact Sciences, where he executed its turnaround and strategic transaction with Genzyme. 

Oct 02, 2017

Doug Fisher, Jeffrey Cossman

Precipio has elected Doug Fisher and Jeffrey Cossman to its board in order to fill existing vacancies. Fisher will serve on Precipio's audit committee and compensation committee. Cossman will serve on the company's compensation committee and will chair the nominating and corporate governance committee. 

Fisher is currently executive-in-resident at venture capital firm InterWest Partners, where he has worked since March 2009. He is also chief business officer at Sera Prognostics. Cossman is founder of the United States Diagnostic Standards, where he also served as CEO and chairman. Prior to that, he was CSO and a member of the board of The Critical Path Institute and as medical director of Gene Logic. 

Sep 29, 2017

Michael Epplen

Michael Epplen has been promoted to president of Sunquest Information Systems. Epplen had been serving as chief operating officer of Sunquest as well as president of Atlas Medical, which Sunquest parent company Roper Technologies acquired two years ago. He previously spent five years as CEO of Data Innovations, another company that Roper bought in 2015.

Sep 29, 2017

Timothy Ring and David Melcher

Becton Dickenson announced today that Timothy Ring and David Melcher have joined its board of directors. Ring has served as chairman and CEO of Bard since August 2003. He previously joined Bard in 1992 and has served as VP of human resources, group VP of Bard International, and in additional roles. Ring is also a director of Quest Diagnostics, a trustee for the New Jersey Health Foundation, and a board member for the Advanced Medical Technology Association. Melcher has been president and CEO of the Aerospace Industries Association since 2015. Prior to AIA, Melcher was president and CEO of Exelis, a spinoff of ITT Corporation. In addition to being a director for Bard, Melcher is also a member of the Federal Aviation Administration's NextGen Advisory Committe, providing advice on policy-level issues for US aviation modernization.  

Sep 27, 2017

Greg Richard

Interpace Diagnostics has promoted Greg Richard to the position of chief commercial officer. He previously served as senior vice president of commercial operations. Richard has worked in the healthcare business in various positions for more than 25 years, starting in sales at Aetna, and then moving to Genentech as the director of managed care. He also served as vice president of managed care for Quest Diagnostics, vice president of sales for the Northeast division of LabCorp, and worked for several privately held companies focused in various areas including specialty CROs, molecular diagnostics, and anatomic pathology services. 

Sep 27, 2017

Eric Brouwer

SQI Diagnostics announced Eric Brouwer has joined the firm as chief scientific officer. He will be responsible for executing SQI's R&D program. Brouwer was most recently CSO of Trinity Biotech and CEO of Trinity's Swedish subsidiary Fiomi Diagnostics. Before that he spent 15 years at Abbott Laboratories. 

Sep 27, 2017

Kathy Hudson

Kathy Hudson has been named chair of the scientific advisory board for Sequence Bio. Hudson will offer expertise in population genomics projects to help the company with its therapeutic discovery efforts. Hudson is CEO of the People-Centered Research Foundation. Previously, she spent eight years leading science policy, legislation, and communications and outreach efforts for the National Institutes of Health. She is the former deputy director for science, outreach, and policy at the NIH, and acted as a senior advisor to the agency's director.

Sep 26, 2017

Jamie Coffin

Sema4, a sequencing and informatics spinout from New York's Mount Sinai Health System, has hired Jamie Coffin as president and chief operating officer. Coffin has more than 20 years of leadership experience in health IT, most recently as CEO of ambulatory surgical EHR vendor Source Medical Solutions. He also was general manager of Dell's former Healthcare and Life Sciences group.

Sep 20, 2017

Olivier Elemento

Olivier Elemento has been named director of the Caryl and Israel Englander Institute for Precision Medicine at Weill Cornell Medicine, succeeding Mark Rubin, the institute's founding director. Elemento was most recently director of the institute's computational biology group. He is also the associate director of the HRH Prince Alwaleed Bin Talal Bin Abdulaziz Alsaud Institute for Computational Biomedicine and co-leader of the Genetics, Epigenetics, and Systems Biology program in the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine. He holds a bachelor's degree in mechanical engineering from University Paul Sabatier, a master's degree in mechanical engineering from INSA Toulouse, and a doctorate in computational biology from the University of Montpellier/CNRS.

Pages

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.